Agile Therapeutics (AGRX) Shares Up 7.2%

Agile Therapeutics Inc (NASDAQ:AGRX) shares shot up 7.2% on Wednesday . The company traded as high as $4.90 and last traded at $4.76. 569,198 shares traded hands during mid-day trading, an increase of 55% from the average session volume of 367,000 shares. The stock had previously closed at $4.44.

A number of research firms have weighed in on AGRX. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 target price on shares of Agile Therapeutics in a report on Thursday, September 21st. HC Wainwright set a $10.00 target price on Agile Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Janney Montgomery Scott reissued a “buy” rating and issued a $13.00 target price on shares of Agile Therapeutics in a report on Thursday, September 7th. Royal Bank of Canada reissued a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Wednesday, October 18th. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $10.20.

The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. equities research analysts forecast that Agile Therapeutics Inc will post -0.99 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new position in shares of Agile Therapeutics in the second quarter worth about $309,000. Dimensional Fund Advisors LP raised its stake in shares of Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after buying an additional 82,213 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of Agile Therapeutics in the second quarter worth about $122,000. Pura Vida Investments LLC raised its stake in shares of Agile Therapeutics by 65.9% in the third quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after buying an additional 115,000 shares during the period. Finally, Caxton Corp raised its stake in shares of Agile Therapeutics by 12.1% in the third quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock worth $8,117,000 after buying an additional 196,445 shares during the period. 72.92% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/12/21/agile-therapeutics-agrx-shares-up-7-2.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply